Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia. Issue 8 (21st April 2016)

• Record Type: Journal Article
• Authors: Samis, Jill; Lee, Paul; Zimmerman, Donald; Arceci, Robert J.; Suttorp, Meinolf; Hijiya, Nobuko
• Is Part Of: Pediatric blood & cancer. Volume 63:Issue 8(2016)
• Page Start: 1332
• Page End: 1338
• Publication Date: 2016-04-21
• Subjects: children -- CML -- endocrine -- growth -- TKI; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.26028
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract : Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long‐term consequences that differ from adults. Children may develop endocrinopathies related to "off‐target" effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long‐term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.